Publications
May 3, 2022 Federal Circuit Affirms Precedential Opinion Panel Decision Limiting the Circumstances In Which the Board Should Raise Sua Sponte Patentability Issues Against Proposed Substitute Claims The Intellectual Property Strategist
March 22, 2022 Coronavirus (COVID-19) Resource Center
January 10, 2022 Pair of Federal Circuit Decisions Address Standing to Appeal Adverse IPR Decision The Intellectual Property Strategist
September 9, 2021 Federal Circuit Clarifies Pleading Requirements for Patent Cases and Affirms Grant of Summary Judgement of Invalidity Under 35 U.S.C. §101 The Intellectual Property Strategist
March 4, 2021 Federal Circuit: Texas Court Abused Its Discretion By Delaying On Venue Transfer Motion While Proceeding With the Merits of the Case (March 2021) The Intellectual Property Strategist
January 8, 2021 What’s Ahead in 2021 for Reverse-Payment Settlement Litigation Bloomberg Law
January 6, 2021 Federal Circuit: Post-Employment Assignment Clause Void Under California Law (January 2021) The Intellectual Property Strategist
November 19, 2020 For the First Time Since TC Heartland, the Federal Circuit Addresses Venue in an ANDA Case – the Holding May Also Impact BPCIA Litigation
May 14, 2019 Federal Circuit Strikes Down Diagnostic Patent in Latest § 101 Decision
December 11, 2018 Fed. Circ. Provides Clarity On Patent Term Questions
August 22, 2018 Beyond the Presumption Against Extraterritoriality
August 1, 2018 PTAB and Bar Prepare for Aftermath of Supreme Court’s SAS Decision
April 13, 2018 Fed. Circ. Case May Change Biosimilar IPR Strategy
February 1, 2018 Patent dance remains on point
December 8, 2017 Mixed Results as IPR Petitions for Biosimilars Soar
October 5, 2017 A New Strain Of Inequitable Conduct Litigation
December 22, 2016 Discontent At Fed. Circ. Grows Post Cuozzo
April 27, 2016 A Breakthrough Technology is Caught in an Epic Patent Battle
March 16, 2016 Biosimilar Makers Turn To IPRs Despite Mixed Results
October 27, 2015 TPP Biologics Exclusivity Period Maintains The Status Quo
June 2015 Biobetters: The Advantages and Challenges of Being Better
June 2015 New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms
October 2014 If High Court Reverses Teva, Litigation Costs May Increase
February 2012 FDA Issues Draft Guidelines for Biosimilars
January 2012 Partnering With The Feds For IP Enforcement: Part 1
June 2011 Supreme Court Decision: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.
May 2011 IP Audits: Making the Most of Your Intellectual Property
April 9, 2010 Federal Circuit Reinvigorates the Written Description Requirement
June 2009 On Appeal Alert: Federal Circuit Grants Mandamus on Motion to Transfer Venue
Spring 2008 IP OnTrial
